SARS-CoV-2 replicon for high-throughput antiviral screening.

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus, which is highly pathogenic and classified as a biosafety level 3 (BSL-3) agent, has greatly threatened global health and efficacious antivirals are urgently needed. The high requirement of facilities to manipulate the live virus has limited the development of antiviral study. Here, we constructed a reporter replicon of SARS-CoV-2, which can be handled in a BSL-2 laboratory. The Renilla luciferase activity effectively reflected the transcription and replication levels of the replicon genome. We identified the suitability of the replicon in antiviral screening using the known inhibitors, and thus established the replicon-based high-throughput screening (HTS) assay for SARS-CoV-2. The application of the HTS assay was further validated using a few hit natural compounds, which were screened out in a SARS-CoV-2 induced cytopathic-effect-based HTS assay in our previous study. This replicon-based HTS assay will be a safe platform for SARS-CoV-2 antiviral screening in a BSL-2 laboratory without the live virus.

Generation and characterization of Japanese encephalitis virus expressing GFP reporter gene for high throughput drug screening.

Japanese encephalitis virus (JEV), a major cause of Japanese encephalitisis, is an arbovirus that belongs to the genus Flavivirus of the family Flaviviridae. Currently, there is no effective drugs available for the treatment of JEV infection. Therefore, it is important to establish efficient antiviral screening system for the development of antiviral drugs. In this study, we constructed a full-length infectious clone of eGFP-JEV reporter virus by inserting the eGFP gene into the capsid-coding region of the viral genome. The reporter virus RNA transfected-BHK-21 cells generated robust eGFP fluorescence signals that were correlated well with viral replication. The reporter virus displayed growth kinetics similar to wild type (WT) virus although replicated a little slower. Using a known JEV inhibitor, NITD008, we demonstrated that the reporter virus could be used to identify inhibitors against JEV. Furthermore, an eGFP-JEV-based high throughput screening (HTS) assay was established in a 96-well format and used for screening of 1443 FDA-approved drugs. Sixteen hit drugs were identified to be active against JEV. Among them, five compounds which are lonafarnib, cetylpyridinium chlorid, cetrimonium bromide, nitroxoline and hexachlorophene, are newly discovered inhibitors of JEV, providing potential new therapies for treatment of JEV infection.

Membrane-associated cytotoxicity induced by realgar in promyelocytic leukemia HL-60 cells.

Realgar has been shown to have a therapeutic effect against acute promyelocytic leukemia (APL) by inducing apoptosis. However, there is little data about the effects of it on plasma membrane. In the present study, the cytotoxicity of realgar to HL-60 cells including its inhibiting cell growth, inducing apoptosis and bringing about membrane toxicity was investigated. It was suggested that realgar could significantly suppress the proliferation of HL-60 cells in a dose-dependent manner by 3-(4,5-dimethylthiazol-2-diphenyl-tetrazolium bromide (MTT) assay and the IC50 value was 5.67 microM. Flow cytometric analysis revealed that treatment with realgar resulted in increased percentages of apoptotic cells in a dose-dependent manner. On the other hand, membrane lipid peroxidation level, lactate dehydrogenase (LDH) leakage and membrane surface topography alterations were investigated to assess the membrane toxicity induced by realgar. Treatment with realgar at different concentrations accelerated membrane lipid peroxidation, potentiated LDH leakage, which was consistent with enhanced disorganization of membrane surface observed by atomic force microscopy (AFM). These results suggested that such membrane toxicity induced by realgar might play an important role in the process of apoptotic induction and could be considered as one of mechanisms underlying the cytotoxicity of realgar.